Compare Modine Manufacturing Company (MOD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Neurocrine Biosciences Inc — how do they compare? Modine Manufacturing Company trades at $188.35 (market cap $10.22B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| MOD | NBIX | |
|---|---|---|
Market Cap | $10.22B | $15.77B |
Sector | Technology | Health |
52-Week High | $306.89 | $185.50 |
52-Week Low | $119.68 | $123.10 |
Enterprise Value | $10.65B | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $192.35, down 1.19% on the day, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth driven by data center cooling demand, with Q2 2026 EPS beating estimates at $1.53 versus $1.30 expected. However, valuation metrics appear stretched with a P/E of 71.77 and EV/EBITDA of 35.15, while profit margins face pressure from supply chain constraints.
The outlook remains positive due to strong data center backlog growth and analyst consensus price target of $305, representing 59% upside potential. Key risks include execution challenges in scaling production and margin compression. With 77% of analysts rating MOD as Buy and no Sell ratings, Wall Street maintains bullish sentiment despite near-term volatility.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
